US_CryoValve_Aortic-Hero-1130x942

CryoValve®

AORTIC ALLOGRAFT

The Ideal Valve for the Endocarditis Patient.

US_CryoValve_Aortic-Product-Highlights-1272x954

Product Highlights

  • Flexibility allows tailoring to conform to distorted roots from infection and radical debridement.1
  • Available as a full aortic root with the attached anterior mitral leaflet to provide options in surgical implantation.1-2
  • Excellent freedom from recurrent endocarditis demonstrated by multiple, long-term studies.1-5

Product Overview

Design Features
1
2

1. Superior Quality

Artivion’s strict donor rejection criteria and proprietary processing provide superior quality allografts. 

2. Excellent Clinical Outcomes

The CryoValve Aortic Allograft demonstrates 85.2 ± 7.7% freedom from recurrent endocarditis at 20 years.1

US_CryoValve_Aortic-Design-Features-2544x1200

The natural handling characteristics of tissue are superior to using any type of prosthetic material.

Dr. Thomas Pollard, United States

Clinical Evidence

Proven Solution for Endocarditis

Infective Endocarditis (IE) is the most severe and potentially devastating complication of heart valve disease.1 CryoValve Aortic Allograft demonstrates exceptional freedom from recurrent endocarditis across multiple studies at 10 years, with several of these cohorts including 20-year follow-up.2-6

CryoValve Clinical Evidence

Product Videos

Artivion Sizing for Heart Valve Allografts

Additional Resources

Explore additional resources for CryoValve® Aortic Allograft below. For further information or to contact a sales associate in your area, contact us.

Ordering Information

DOWNLOAD

Allograft MRI Information Letter

DOWNLOAD

White Paper: Large Aortic Valve Allograft

DOWNLOAD

Product Highlights

  1. Sabik JF, et. al. (2002). Aortic Root Replacement with Cryopreserved Allograft for Prosthetic Valve Endocarditis. Ann Thorac Surg, 74(3), 650-9.
  2. Solari S, et. al. (2016). Over 20 years experience with aortic homograft in aortic valve replacement during acute infective endocarditis. Eur J Cardiothorac Surg, 50(6), 1158-64.
  3. Doty JR, et. al. (1998). Aortic Valve Replacement With Cryopreserved Aortic Allograft: Ten-Year Experience. J Thorac Cardiovasc Surg, 115(2), 371-80.
  4. Musci M, et. al. (2010). Homograft aortic root replacement in native or prosthetic active infective endocarditis: twenty-year single-center experience. J Thorac Cardiovasc Surg, 139(3), 665-73.
  5. Yankah AC, et. al. (2002). Surgical management of acute aortic root endocarditis with viable homograft: 13-year experience. Eur J Cardiothorac Surg, 21(2), 260-7.

Product Overview

  1. Solari S, et. al. (2016). Over 20 years experience with aortic homograft in aortic valve replacement during acute infective endocarditis. Eur J Cardiothorac Surg, 50, 1158-64. 

Clinical Evidence

  1. Pettersson GB, et. al. (2017). The American Association for Thoracic Surgery (AATS) consensus guidelines: Surgical treatment of infective endocarditis: Executive summary. J Thorac Cardiovasc Surg, 153(6), 1241-58.
  2. Sabik JF, et. al. (2002). Aortic Root Replacement with Cryopreserved Allograft for Prosthetic Valve Endocarditis. Ann Thorac Surg, 74(3), 650-9.
  3. Musci M, et. al. (2010). Homograft aortic root replacement in native or prosthetic active infective endocarditis: twenty-year single-center experience. J Thorac Cardiovasc Surg, 139(3), 665-73.
  4. Yankah AC, et. al. (2002). Surgical management of acute aortic root endocarditis with viable homograft: 13-year experience. Eur J Cardiothorac Surg, 21, 260-67.
  5. Solari S, et. al. (2016). Over 20 years experience with aortic homograft in aortic valve replacement during acute infective endocarditis. Eur J Cardiothorac Surg, 50(6), 1158–64.
  6. Witten J, et. al. (2021). Performance and Durability of Cryopreserved Allograft Aortic Valve Replacement. Ann Thorac Surg, 111(6), 1893-900.

All products and indications are not available/approved in all markets. All trademarks are owned by Artivion, Inc. or its subsidiaries. On-X Life Technologies, Inc., Jotec GmbH, and Ascyrus Medical GmbH are wholly owned subsidiaries of Artivion, Inc. MLENG1593.000. (2023-04)

Artivion, Inc., 1655 Roberts Blvd NW, Kennesaw, GA 30144, US